Frankfurt - Delayed Quote EUR

Novartis AG (NOTA.F)

95.60

-0.40

(-0.42%)

At close: May 12 at 3:05:52 PM GMT+2

Drugmakers Avoid Worst-Case Pricing Scenario for Now

An executive order says if companies and the government don’t align on tying U.S. drug prices to other countries, the administration will impose its own plan.

The Wall Street Journal 6 hours ago

BMY

CELG-RT

NVS
European Equities Close Higher in Monday Trading as US, China Truce Relieves Investors

The European stock markets closed higher in Monday trading as investors were encouraged by a 90-day

PREMIUM
MT Newswires 12 hours ago

STLAM.MI

^FTSE

NVS
Market Chatter: Novartis to Continue Malaria Drug Production Despite Uncertain Demand

Novartis (NVS) will keep manufacturing treatments for malaria and leprosy even if regular orders sto

PREMIUM
MT Newswires 16 hours ago

NVS
Trump’s Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks

Drugmakers' shares fell globally after President Trump said he would sign an executive order to lower the cost of prescription drugs. Shares of Japan's Daiichi Sankyo, which gets about a third of revenue from the U.S., dropped around 8%. Other Japanese drug stocks also fell.

The Wall Street Journal 17 hours ago

AZN

AZNCF

PFE
Novartis to keep making malaria drugs if orders dry up amid aid cuts

LONDON (Reuters) -Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding crunch, its president of global health told Reuters in an interview. The company makes 28 million malaria treatment courses every year, and sells almost all of them a not-for-profit price to countries and groups including the President's Malaria Initiative (PMI), a U.S.-government funded initiative that still has an unclear future given President Donald President Trump's vast international aid cuts, although it did receive an exemption for some work earlier this year because of its lifesaving potential. "We are not going to be the bottleneck," said Dr Lutz Hegemann in an interview.

Reuters 21 hours ago

NVS
Here's Why Novartis (NVS) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 3 days ago

NVS
Q1 2025 Schrodinger Inc Earnings Call

Q1 2025 Schrodinger Inc Earnings Call

Thomson Reuters StreetEvents 4 days ago

NVS

SDGR
Schrodinger Inc (SDGR) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...

Schrodinger Inc (SDGR) reports a 63% revenue increase, driven by software and drug discovery growth, while maintaining a robust cash position.

GuruFocus.com 4 days ago

SDGR

NVS
Novartis (NVS) is a Great Momentum Stock: Should You Buy?

Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks 7 days ago

NVS
Why Novartis (NVS) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.

Zacks 7 days ago

NVS
Novartis to buy Regulus Therapeutics for as much as $1.7 billion

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion.

LA Times 10 days ago

NVS

RGLS
Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 6,307% surge in interest CG Oncology (CGON), 3,377% surge in interest Chemomab Therapeutics (CMMB), 3,029% surge in interest BioCardia (BCDA), 1,244% surge in interest Senti Biosciences (SNTI), 1,175% surge in interest Tevogen Bio Holdings (TVGN), 332% surge in interest Regulus Therapeutics (RGLS), 223% surge in interest Spr

TipRanks 11 days ago

NVS

NVSEF

RGLS
Novartis to strengthen renal disease portfolio with Regulus

Total consideration for the acquisition, including the CVR, could reach $1.7bn.

Pharmaceutical Technology 11 days ago

NVS

RGLS
Why Novartis (NVS) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 12 days ago

NVS
Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks 12 days ago

EXAS

NVS
Novartis to acquire Regulus in deal for kidney disease drug

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance microRNA technology.

BioPharma Dive 12 days ago

NVS

RGLS
Novartis to Acquire Regulus in $1.7 Billion Deal

With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus.

The Wall Street Journal 12 days ago

NVS

NVSEF

RGLS
Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal

(Reuters) -Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease. Under the deal terms, Novartis will pay $7 per share in cash upfront, or about $800 million, and another $7 per share to Regulus shareholders if the lead drug candidate, farabursen, gets regulatory approval, the California-based biotech said on Wednesday. The deal, expected to bolster Novartis' lineup of kidney disease drugs in development, will also give the company access to Regulus' proprietary platform to develop treatments targeting a type of genetic material called microRNAs.

Reuters 12 days ago

NVS

RGLS
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal diseaseLead asset for ADPKD, farabursen, is a novel, next-generation oligonucleotide targeting miR-17 that recently completed a Phase 1b multiple-ascending dose clinical trial Transaction includes USD 0.8 billion upfront with a potential additional USD 0.9 billion payment upon the achievement of a future regulatory milestone;

GlobeNewswire 12 days ago

NVS

NVSEF
Novartis AG (NVS) Q1 2025 Earnings Call Highlights: Impressive Growth and Strategic Advancements

Novartis AG (NVS) reports robust sales and income growth, while navigating challenges and enhancing its product pipeline.

GuruFocus.com 12 days ago

NVS

Performance Overview

Return	NOTA.F	MSCI WORLD (^990100-USD-STRD)
YTD	+7.83%	+2.13%
1-Year	+7.83%	+11.06%
3-Year	+41.66%	+43.18%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novartis AG (NOTA.F)

Drugmakers Avoid Worst-Case Pricing Scenario for Now

European Equities Close Higher in Monday Trading as US, China Truce Relieves Investors

Market Chatter: Novartis to Continue Malaria Drug Production Despite Uncertain Demand

Trump’s Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks

Novartis to keep making malaria drugs if orders dry up amid aid cuts

Here's Why Novartis (NVS) is a Strong Momentum Stock

Q1 2025 Schrodinger Inc Earnings Call

Schrodinger Inc (SDGR) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...

Novartis (NVS) is a Great Momentum Stock: Should You Buy?

Why Novartis (NVS) is a Great Dividend Stock Right Now

Novartis to buy Regulus Therapeutics for as much as $1.7 billion

Biotech Alert: Searches spiking for these stocks today

Novartis to strengthen renal disease portfolio with Regulus

Why Novartis (NVS) is a Top Value Stock for the Long-Term

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Novartis to acquire Regulus in deal for kidney disease drug

Novartis to Acquire Regulus in $1.7 Billion Deal

Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal

Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

Novartis AG (NVS) Q1 2025 Earnings Call Highlights: Impressive Growth and Strategic Advancements

Performance Overview